Beam Therapeutics(US:BEAM)2025-11-04 12:06Financial Performance - Beam Therapeutics ended Q3 2025 with $1.1 billion in cash, cash equivalents, and marketable securities, an increase from $850.7 million at the end of 2024, providing a cash runway expected to support operations into 2028[7][9] - The net loss for Q3 2025 was $112.7 million, or $1.10 per share, compared to a net loss of $96.7 million, or $1.17 per share, in Q3 2024[9][16] - Total operating expenses for Q3 2025 were $136.5 million, compared to $120.8 million in Q3 2024, marking an increase of approximately 13%[9][16] - Research and Development (R&D) expenses for Q3 2025 were $109.8 million, compared to $94.3 million in Q3 2024, reflecting a year-over-year increase of approximately 16%[9][16] Clinical Trials and Developments - Beam plans to present updated data from the BEACON Phase 1/2 trial of BEAM-101 at the American Society of Hematology (ASH) Annual Meeting scheduled for December 6-9, 2025[4][5] - The first subject was dosed in a Phase 1 healthy volunteer trial of BEAM-103, an anti-CD117 monoclonal antibody, as part of the ESCAPE platform[4][9] - The BEAM-302 Phase 1/2 study in alpha-1 antitrypsin deficiency has commenced dosing in a multi-dose cohort evaluating two 60 mg doses administered eight weeks apart[4][9] - Beam expects to report data from the dose-escalation portions of the BEAM-302 trial and provide a clinical development update in early 2026[9][10] - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101 for the treatment of sickle cell disease, supporting its development[9][10] Collaborations and Partnerships - Beam's collaboration with Orbital Therapeutics is highlighted by Bristol Myers Squibb's proposed acquisition of Orbital for $1.5 billion, with Beam holding a 17% stake[3][9]